Atkins, M. B., Azambuja, A. A., Robert, C., Dummer, R., Lebbé, C., Nathan, P. D., Melo, A. C. D., Utyashev, I. A., Neyns, B., Marquez-Rodas, I., Moser, J. C., Shaw, H. M., Giacomo, A. M. D., Wu, W., Grossman, J. E., O'Day, S., Ott, P. A., Schadendorf, D., Couselo, E. M., Ascierto, P. A. (2026). Botensilimab (BOT) ± balstilimab (BAL) in patients (pts) with advanced cutaneous melanoma (cMEL) refractory/resistant (R/R) to anti–PD-(L)1 ± CTLA-4: A phase 2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.9543